A new level of collaboration is needed to overcome the current and future challenges facing healthcare globally, according to international research presented recently.
Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reporte